Reply to J.S. Abrams et al

Affiliations

¹ Dana Farber-Cancer Institute, Harvard Medical School, Boston, MA david_steensma@dfci.harvard.edu.
² The University of Texas MD Anderson Cancer Center, Houston, TX.

Comment

David P Steensma et al. J Clin Oncol. 2014.

. 2014 Aug 10;32(23):2516.

doi: 10.1200/JCO.2014.56.3882. Epub 2014 Jul 7.

¹ Dana Farber-Cancer Institute, Harvard Medical School, Boston, MA david_steensma@dfci.harvard.edu.
² The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Comment on

Impact of cancer research bureaucracy on innovation, costs, and patient care.
Steensma DP, Kantarjian HM. Steensma DP, et al. J Clin Oncol. 2014 Feb 10;32(5):376-8. doi: 10.1200/JCO.2013.54.2548. Epub 2014 Jan 6. J Clin Oncol. 2014. PMID: 24395852 No abstract available.
Improving the protocol implementation process: the National Cancer Institute's response.
Abrams JS, Mooney M, Zwiebel J, Friedman S. Abrams JS, et al. J Clin Oncol. 2014 Aug 10;32(23):2515-6. doi: 10.1200/JCO.2014.55.5912. Epub 2014 Jul 7. J Clin Oncol. 2014. PMID: 25002734 No abstract available.